Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.59 |
| ▸ | DRD2 | P14416 | 7/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185349 | 0.96 | LTA4H (0.55) | LTA4HDRD2L3MBTL1DRD1DRD3 | |
| SCHEMBL4182249 | 0.87 | LTA4H (0.61) | LTA4HDRD2L3MBTL1PTGS2DRD1 | |
| SCHEMBL4177226 | 0.87 | LTA4H (0.58) | LTA4HDRD2L3MBTL1KDM1AKDM4E | |
| SCHEMBL4174980 | 0.87 | LTA4H (0.71) | LTA4HDRD2L3MBTL1PTGS2MCHR1 | |
| SCHEMBL4183852 | 0.84 | DRD2 (0.60) | LTA4HDRD2L3MBTL1PTGS2DRD1 | |
| SCHEMBL4182228 | 0.84 | LTA4H (0.55) | LTA4HDRD2L3MBTL1KDM4EHRH3 | |
| SCHEMBL4188794 | 0.83 | LTA4H (0.66) | LTA4HDRD2L3MBTL1DRD1DRD3 | |
| SCHEMBL1728913 | 0.82 | HRH3 (0.51) | LTA4HKCNH2KDM1AHRH3 | |
| SCHEMBL1730234 | 0.82 | EPAS1 (0.47) | LTA4HDRD2L3MBTL1KCNH2MAPK14 | |
| SCHEMBL1730942 | 0.80 | EPAS1 (0.45) | LTA4HDRD2L3MBTL1KCNH2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | claimed |
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | SIGMAR1, OPRL1, OPRK1 | LTA4H 2891/4885DRD2 61/4885L3MBTL1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.